The Coretec Group Announces Full Details of its March 14 Shareholder Call and Presentation

The Company will update its shareholders on its definitive share exchange agreement with Core Optics and how it will strengthen Coretec’s structure and operations, and spur revenue and the commercialization of Endurion

ANN ARBOR, Mich., March 11, 2024 (GLOBE NEWSWIRE) — The Coretec Group (OTCQB: CRTG), developers of silicon anode active materials for lithium–ion batteries, and cyclohexasilane (CHS) for EV, cleantech, and 3D display technology, today announced the details of its upcoming shareholder call and presentation on March 14, 2024, at 10:00 am EDT.

Coretec Chief Executive Officer Matthew Kappers and Chief Financial Officer Matthew Hoffman, as well as Core Optics CEO Dr. Seonkee Kim, will discuss the details of Coretec’s recent definitive share exchange agreement announcement with Core Optics, LLC and provide an update on the commercialization progress of its Endurion battery program that represents an ideal fit for Core Optics’ customer base.

Company leadership will highlight Core Optics’ product and customer pipeline, as well as the market demand for each respective category; the South Korea–based factory and personnel driving customer acquisition and R&D; and the synergies between the two brands. Notably, they will elaborate on Core Optics’ position in the compact camera modules (CCM) industry and how it will further the advancement of C–Space, as well as the commercialization efforts for the Endurion battery development program.

CFO/COO Matt Hoffman will provide an update on Endurion, and how Core Optics’ existing customer relationships and commercial pipeline will position the battery program for advancement, evaluation, and adoption. Notably, Hoffman will detail the laboratory expansion and how test results will fuel partnerships and further commercial activity.

Finally, leadership will detail the Company’s new leadership structure for the shareholder community, customer base in key markets, and broader listening audience.

Shareholders and other interested parties can register for the 10:00 am EDT, March 14, 2024 call at the links below.

Participants / Audience

Webcast Registration Link: https://edge.media–server.com/mmc/p/ikba429s

Call Registration Link: https://register.vevent.com/register/BI3b8b187f1fa84b5f89793401ab3e3982

About The Coretec Group

The Coretec Group, Inc. is an Ann Arbor, Michigan–based developer of engineered silicon and is using its expertise to develop silicon anodes for lithium–ion batteries that will charge faster and last longer. This program is called Endurion. Silicon has the theoretical ability to hold up to 10x the amount of lithium–ions as compared to traditional graphite. Through its proprietary micron and nanoparticle approach, Endurion is loading silicon into the battery anode. A modest increase in silicon will be a game changer that will revolutionize the EV market as well as other energy storage applications.

Additionally, the Company is using its engineered silicon to develop a portfolio of other energy–focused products, including solid–state lighting (LEDs), semiconductors, and printable electronics. Coretec continues to develop CSpace, its 3D volumetric display technology with a wide array of applications including medical imaging, automotive, and others.

For more information, please visit thecoretecgroup.com.

About Core Optics

Core Optics LLC, a Virginia limited liability company, runs its operations through its Korean subsidiary, Core Optics Co., Ltd. Core Optics Co., Ltd. was established in 2023 after acquiring a compact camera module testing equipment product line. It is renowned for its involvement in a high–value enterprise centered around the production and distribution of inspection equipment tailored for compact camera modules (CCM) used in smartphones and automobiles.

For more information, please visit https://www.coreoptics.us/

Follow The Coretec Group on

X (Formerly Twitter) – @CoretecGroupInc
LinkedIn – www.linkedin.com/company/24789881
YouTube – www.youtube.com/channel/UC1IA9C6PoPd1G4M7B9QiZPQ/featured

Forward–Looking Statements

The statements in this press release that relate to The Coretec Group’s expectations with regard to the future impact on the Company’s results from operations are forward–looking statements and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the Company’s actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward–looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

Corporate Contact:

The Coretec Group, Inc.
Lindsay McCarthy
info@thecoretecgroup.com 
+1 (866) 916–0833

Media Contact:

Spencer Herrmann
FischTank PR
coretec@fischtankpr.com 
+1 (518) 669–6818


GLOBENEWSWIRE (Distribution ID 9061465)

Fortrea Signs Definitive Agreement to Divest Endpoint Clinical and Patient Access Businesses to Arsenal Capital Partners

Proposed divestiture of Endpoint Clinical and Fortrea Patient Access businesses further streamlines Fortrea’s strategic focus as a pure–play contract research organization

Creates standalone best–in–class Randomization and Trial Supply Management and Patient Access solutions positioned for differentiation and growth

DURHAM, N.C., March 11, 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced it has signed a definitive agreement to divest assets relating to its Enabling Services segment, namely its Endpoint Clinical (“Endpoint”) and Fortrea Patient Access businesses, to Arsenal Capital Partners (“Arsenal”), a leading private equity firm specializing in building market–leading, technology–rich healthcare companies.

By divesting these businesses, Fortrea aims to advance the growth strategy and solutions of Endpoint and Fortrea Patient Access, positioning them for increased investment to accelerate the technology roadmap and further enhance operations to support best–in–class customer solutions and delivery. The remaining business of Fortrea will strengthen its focus on clinical development phases 1 through 4. Closing is targeted for the second quarter of 2024, subject to customary closing conditions and regulatory approvals, as well as the parties entering into certain services and operating agreements.   

“Today marks a significant milestone in Fortrea’s ongoing journey, as we sharpen our focus on organically growing as a pure–play CRO, with added financial flexibility,” said Fortrea Chairman and CEO Tom Pike. “After undertaking a strategic review of our business, divesting Endpoint and Fortrea Patient Access aligns with the interests of our customers. Arsenal has extensive experience in building businesses that create systematic improvement in health outcomes, and I am confident that Endpoint and Fortrea Patient Access will be able to strengthen their market positions, nurture top–tier talent and invest in new capabilities and resources while delivering solutions that improve patients’ lives.”

“I am excited for this next chapter for Endpoint and Fortrea Patient Access,” said Sam Osman, president of Enabling Services at Fortrea, who will serve as the CEO of these businesses with Arsenal. “These businesses will be distinctively positioned to effectively manage the patient journey across clinical trials and into commercialization by driving patient access and adherence for approved therapies. Combining Arsenal’s deep investment acumen and leading industry operational expertise, I am confident the Endpoint and Fortrea Patient Access businesses are well positioned for growth and delivery of enhanced capabilities for patients and pharma sponsors. I look forward to our continued positive impact on healthcare.”

“Endpoint and Fortrea Patient Access have a proud, decades–long track record of market leadership in supporting clinical research and commercialization of innovative therapies. Arsenal takes pride in building organizations that meaningfully improve healthcare. We are excited to partner with management and employees to accelerate the growth of these two businesses,” said Gene Gorbach, an Investment Partner of Arsenal.

Dimitris Agrafiotis, Ph.D., Director of Digital, Analytics & AI at Arsenal said, “Endpoint and Fortrea Patient Access provide essential solutions that enable patients’ participation in clinical trials and access to therapies. I am delighted to support the talented team at Endpoint and Fortrea Patient Access. Together, we will further enhance the sophistication of technology capabilities that underpin these companies’ commitment to delivering the highest quality services to the pharmaceutical industry.”

Endpoint Clinical
Endpoint operates in the high growth eClinical market as a leading provider of Randomization and Trial Supply Management (RTSM) solutions to biopharmaceutical and CRO customers with expertise in serving complex and late–stage clinical trials. For more than 15 years, Endpoint has had a successful track record of effectively supporting more than 1,750 clinical trials involving 875,000 patients across 90 countries and has cultivated a blue–chip customer base and nurtured long–standing strategic relationships.

Fortrea Patient Access
Fortrea Patient Access is a scaled leader in the HUB services and patient access market, serving the biopharmaceutical industry with comprehensive patient support, product access, affordability and adherence solutions for more than 30 years. Further advanced by its recently expanded non–commercial specialty pharmacy, FortreaRx™, to support enhanced distribution of cold–chain and ambient free goods products, Fortrea Patient Access is committed to driving patient outcomes and improving healthcare accessibility through its extensive experience while currently supporting more than 2.5 million patients and over 100 unique brands across more than 25 disease indications.

Arsenal Capital Partners
Arsenal Capital Partners is a leading private equity investment firm that specializes in building market–leading industrial growth and healthcare companies. Since its inception in 2000, Arsenal has raised institutional equity investment funds totaling over $10 billion, completed more than 290 platform and add–on acquisitions, and achieved more than 35 realizations. The firm works with management teams to build strategically important companies with leading market positions, high growth, and high value–add.  For more information, visit www.arsenalcapital.com.

Advisors
Barclays is serving as exclusive financial advisor to Fortrea, and Smith Anderson is serving as its legal counsel. Sidley Austin LLP served as Arsenal’s legal counsel.

Earnings Call and Replay
Fortrea will discuss the divestiture announcement on its fourth quarter 2023 earnings conference call, which will be held today at 9:00 am ET. The conference can be accessed through the Fortrea Investor Relations website or the following earnings webcast link. To avoid potential delays, please join at least 10 minutes prior to the start of the call. A replay of the live conference call will be available shortly after the conclusion of the event and accessible on the events and presentations section of the Fortrea website. A supplemental slide presentation will also be available on the Fortrea Investor Relations website prior to the start of the call.

About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I–IV clinical trial management, clinical pharmacology, consulting services, differentiated technology–enabled trial solutions and post–approval services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team of about 18,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter) @Fortrea.

Cautionary Statement Regarding Forward–Looking Statements

This press release contains “forward–looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward–looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the anticipated benefits of the transaction, including future financial and operating performance, and the anticipated timing for completing the transaction. In this context, forward–looking statements often address expected future business and financial performance and financial condition, and often contain words such as “guidance,” “expect,” “assume,” “anticipate,” “intend,” “plan,” “forecast,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words that are intended to identify forward–looking statements, although not all forward–looking statements contain these identifying words. Actual results could differ materially from these forward looking statements due to a number of factors, including, but not limited to: satisfaction of the conditions precedent to consummation of the proposed divestiture of Endpoint Clinical and Fortrea Patient Access businesses transaction, including the ability to secure regulatory approvals, and the Company’s ability to complete the transaction in a timely manner or at all; the possibility that the transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events; the parties’ ability to meet expectations regarding the accounting and tax treatments of the proposed transaction; and other factors described from time to time in documents that the Company files with the SEC. For a further discussion of the risks relating to the Company’s business, see the “Risk Factors” Section of the Company’s Registration Statement on Form 10, as filed with the Securities and Exchange Commission (the “SEC”), as such factors may be amended or updated from time to time in the Company’s subsequent periodic and other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included or incorporated by reference in this report and in the Company’s filings with the SEC. All forward–looking statements are made only as of the date of this report and the Company does not undertake any obligation, other than as may be required by law, to update or revise any forward–looking statements to reflect future events or developments.

Fortrea Contacts:
Hima Inguva (Investors) – 877–495–0816, hima.inguva@fortrea.com
Sue Zaranek (Media) – 919–943–5422, media@fortrea.com
Kate Dillon (Media) – 646–818–9115, kdillon@prosek.com

Arsenal Contact:
Jackie Schofield at  pro–Arsenal@prosek.com


GLOBENEWSWIRE (Distribution ID 9061141)

Recursion Announces Plans to Open New Office in London

LONDON, March 11, 2024 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced plans to open a new office in London’s vibrant King’s Cross neighborhood. Set to formally open in June 2024, the site will provide Recursion and Valence Labs, the company’s artificial intelligence research engine, access to world–class talent across Europe’s rapidly growing TechBio sector and embed Recursion in a thriving innovation ecosystem of leading technology and life science companies.

“As Recursion continues to lead and define the TechBio industry, it's critical we hire the best possible talent, much of which is located in Europe,” said Chris Gibson, Ph.D., Co–founder and CEO at Recursion. “London stood out as an ideal location given its brilliant and interdisciplinary talent across the fields of technology, biology and chemistry. It’s also the epicenter for the rapidly growing TechBio sector in Europe, where leading technology and life science companies like Google and Merck both sit within walking distance of our new Recursion site. I look forward to expanding our operations in Europe and hiring many new Recursionauts who will help us advance our mission of decoding biology to radically improve lives.”

To support Recursion’s leadership in TechBio and entry into London, the company is excited to announce the addition of Michael Bronstein, DeepMind Professor of Artificial Intelligence at Oxford University, as a Scientific Advisor. Professor Bronstein is a world leader in geometric deep learning, graph neural networks, and protein design. Professor Bronstein joins AI luminary Professor Yoshua Bengio in supporting Recursion and Valence Labs in the development of state–of–the–art AI models to support the industrialization of drug discovery.

“Recursion is leading the field in advancing cutting–edge AI research for real–world applications with the potential to radically improve lives, and I’m honoured to join them in their mission,” said Prof Michael Bronstein. “I have collaborated with Valence prior to their acquisition by Recursion, and I look forward to continuing to work with the team to advance this important work, especially as Recursion continues to grow in London.”

Recursion’s 6,700 square foot London office will be located at 3 Pancras Square, King’s Cross London. The building is part of a 67–acre redevelopment project in the heart of King’s Cross, with over 4.5 million square feet of office space. Located within a 3–minute walk from King’s Cross Station and St. Pancras International, the site offers excellent transit access. The building includes an onsite cafe, bicycle storage, showers, prayer room and mothers room. In line with Recursion’s commitment to sustainability, the building meets the requirements for an “Excellent” rating by BREEAM building standards and is linked to a site–wide district heating and cooling network that results in net–zero carbon emissions.

“The UK Government’s plan for attracting more inward investment into the UK is working. Recursion’s investment is yet another vote of confidence in the UK, our top talent and our amazing tech and life sciences industries,” said Investment Minister Lord Johnson. “I’m delighted Recursion has chosen London, and we’ll continue to do everything we can to ensure the UK remains the top choice for investments like this.”

Today, Recursion has over 500 employees with a near–equal mix of life scientists and technologists across sites in Salt Lake City, Toronto, Montréal, and the San Francisco Bay Area. Recursion’s new London office will serve as an extension of both Recursion and Valence Labs’ teams. To launch recruiting efforts for the new site, Recursion has opened multiple new roles across technology and biology functions with immediate plans to hire the first 20 people to be based out of the new London office. Recursion and Valence Labs will also host a TechBio Mixer tomorrow, March 12, at the location of its new site to celebrate the office and network with the TechBio community.

For more information on open positions and to apply, visit recursion.com/careers and valencelabs.com/careers.

About Recursion
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological, chemical and patient–centric datasets. Recursion leverages sophisticated machine–learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology, chemistry and patient–centric data to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montreal and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on X (formerly Twitter) and LinkedIn.

Media Contact
Media@Recursion.com

Investor Contact
Investor@Recursion.com

Forward–Looking Statements
This document contains information that includes or is based upon “forward–looking statements'' within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding the opening of the London office and timing of such opening; the recruitment efforts and number of roles at the London office; and all other statements that are not historical facts. Forward–looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “could,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10–K for the Fiscal Year Ended December 31, 2023. All forward–looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.

 


GLOBENEWSWIRE (Distribution ID 9060948)

It’s Africa’s Time To Shine, says UN Under Secretary Claver Gatete

Economic Commission for Africa’s Executive Secretary, Claver Gatete. Credit: ECA

Economic Commission for Africa’s Executive Secretary, Claver Gatete. Credit: ECA

By Busani Bafana
VICTORIA FALLS, Zimbabwe, Mar 11 2024 – With 20 percent of the global population and vast untapped natural resources, not forgetting its human capital, it is time Africa had its rightful seat at the global table, the United Nations Under Secretary and Executive Secretary of the Economic Commission for Africa (ECA), Claver Gatete, has called.

Decrying that Africa has been on the back foot on the global stage when key political and economic decisions are made, Gatete says it is time Africa claimed its voice. Gatete told a recent conference of African finance ministers in Victoria Falls, Zimbabwe, that Africa is in a financial and fiscal crisis because a global financial system does not have the interests of the continent at heart.

Africa Must Be Heard

“So, what will it take for African countries to really feel heard? Gatete asked.

“It is okay for us to say that 80 years ago, Africa was not at the table. It is probably acceptable to say that when the Millennium Development Goals were adopted, we were also at the periphery,” he said, adding, “But we will not be forgiven today if we do not occupy center stage as architects of a new global financial architecture that works for us.”

Africa, he noted, was facing multiple crises that it was not directly responsible for but bore the worst impacts from the Ukraine-Russia war, COVID-19, and high indebtedness to climate change.

The financial difficulties that Africa is currently facing are not solely the result of COVID-19 or recent conflicts but also have their roots in an inadequate global financial architecture and a multilateral financial system that does not adequately serve Africa’s needs, Gatete told IPS.

The African Union is pushing for Africa to have a permanent seat in the UN Security Council. Credit: Busani Bafana/IPS

The African Union is pushing for Africa to have a permanent seat in the UN Security Council. Credit: Busani Bafana/IPS

Referring to the creation of the UN in 1945, Gatate pointed out that the five permanent members of the Security Council—China, the United States, the United Kingdom, France, and Russia—made up almost 50 percent of the world’s population then, but today that figure is just 26 percent.

“While Africa now represents nearly 20 percent of the global population, it is not represented at the G7, whose proportion of the global population is only 9.7 percent. So how do you solve today’s problems with outdated 80-year old structures that do not reflect the global shifts that have occurred?”

Africa has long pushed for a seat on the UN Security Council, calling for the reform of the United Nations in line with the Ezulwini Consensus, agreed in 2022. The Ezulwini Consensus is a position on international relations and UN reform agreed upon by the African Union. Africa wants at least two permanent seats and five non-permanent Security Council seats chosen by the African Union. 

Addressing the third summit of a group of developing countries (G77) in Uganda in January this year, UN Secretary General, Antonio Guterres said there is agreement for Africa’s representation on the Security Council.

“So for the first time, I’m hopeful that at least a partial reform of the UN Security Council could be possible for this flagrant injustice to be corrected and for Africa to have at least one permanent member in the Security Council,” Guterres said.

A Green Transition Good for Africa

Highlighting that a productive green finance system in Africa has the potential to generate USD 3 trillion by 2030, Gatete urged that Africa needs to move from ‘potential’ to tangible actions with bankable regional projects.

Innovative instruments like debt-for-nature swaps, regional blue bonds, natural capital accounting, and regional carbon markets can provide financing that addresses debt issues and fosters environmental action, he noted, emphasizing that Africa wants a fair price for carbon trading.

“It does not make sense for African countries to earn less than USD 10 per ton of carbon while countries in Europe earn over USD 100.”

A Call to Change the Global Financial Architecture

It is estimated that Africa spends nearly USD 100 billion on debt repayments annually, forcing many governments to defer investments in social spending on health, education, and food security.

ECA Deputy Executive Secretary and Chief Economist, Hanan Morsy, weighed in, saying there is a need to reduce the debt burden on African countries to enable them to allocate more resources to critical sectors like healthcare and education instead of high debt service costs.

“It is imperative to enhance Africa’s voice and representation, shifting from being rule takers to rule makers,” said Morsy, adding, “This involves bolstering international cooperation on taxation and combating IFFs, including reducing tax evasion and profit shifting.”

Deputy Chairperson of the African Union Commission, Monique Nsanzabaganwa, said Africa’s potential to reclaim its long-overdue rightful treatment was materializing as the global landscape took multi-polar shapes and the African Union became a full member of the G20.

“Africa is stronger together,” Nsanzabaganwa said, adding, “I will argue that the value proposition of the African Union is indeed to foster coherence in our strategies and amplify our common voice.”

IPS UN Bureau Report

 


!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);  

Netanyahu Is Rendering Israel Morally Bankrupt

Whole neighborhoods have been wiped-out in northern Gaza. Credit: 2024 UNRWA Photo by Abdallah El Hajj

By Alon Ben-Meir
NEW YORK, Mar 11 2024 – Israel must uphold its moral values and make every effort to spare the lives of innocent Palestinians as it pursues Hamas’ destruction.

The unfathomable massacre of Israeli Jews by Hamas and its insatiable thirst for Jewish blood has rightfully evoked the most virulent condemnation from many corners of the world, including many Arab states. The call for revenge and retribution by many Israelis was an instinctive human reaction that can be justified in a moment of incomparable rage and devastation.

In this case, the Israelis’ reaction transcended Hamas’ massacre because it brought to life memories from the Holocaust that the Jews foresworn to never let happen again. But it happened, though on a much smaller scale; the savagery and the cold-bloodedness that characterized Hamas’ attack was reminiscent of the Holocaust, which is etched in the mind and soul of the Jews.

Israel’s decision to crush Hamas as a political movement, destroy its infrastructure, and prevent it from reconstituting itself is necessary, and it should relentlessly be pursued with vigor. Under no circumstances and regardless of what the Jews have experienced, however, can the Israeli military justify any acts of revenge against innocent Palestinian men, women, and children who have nothing to do with Hamas’ evil act.

None of the dead or injured Palestinian women and children were asked by Hamas’ leaders whether they should go and massacre innocent Israelis at an unprecedented scale. Although Hamas knew full well the unimaginable price these ordinary Palestinians would end up paying, Hamas was more than willing let them die by the tens of thousands as the sacrificial lamb on the altar of the most vicious beasts that roam the earth.

After more than six months of fighting that inflicted horrific death and destruction on Gaza and claimed the lives of more than 30,000, two-thirds of them women and children, while laying half of Gaza in utter ruin, one must ask the question: was there a strong element of revenge that contributed to this colossal human disaster? Tragically, the answer is YES.

The role of the victim is deeply ingrained in the Jewish psyche, and the leap from being victim to victimizer is subconscious; acting on it is spontaneous. That said, the extent and the scope of the Israeli reaction calls into question whether or not Israeli soldiers have been engaged in acts of revenge beyond their legitimate right to self-defense while pursuing Hamas’ operatives.

When we see in real-time the destruction of one neighborhood after another, horrendously transcending any proportionality of collateral damage which is often unavoidable in a state of war, we see revenge and retribution.

When soldiers boast of serving in the most moral military force in the world but laugh and dance following the explosion and leveling of a residential building to the ground, killing dozens of civilians among one or two suspected Hamas fighters, it is not an act of self-defense, it is an act of vengeance that defies the logic of what’s moral.

When the entire population of Gaza is facing “catastrophic levels of acute food insecurity” and hundreds of children are dying from curable illnesses because they could not receive the medical treatment and the medicine they need, it is an unforgivable crime the whole world is watching in real-time with revulsion and disdain.

When a majority of the Palestinians are forced to evacuate their homes with women and children, and the sick are forced to walk for miles with little or no rations, not knowing where they will sleep and where the next meal will come from, it is cruel and devoid of any moral culpability.

When an entire family is buried alive under the rubble of their building that collapsed over their heads, and they die a slow death before the rescuers and medical teams can save anyone, it is inhuman and severely damages the high moral ground the Israeli army has proudly claimed.

More than 25,000 women and children have been killed in Gaza, including 258 babies who never had the chance to celebrate their first birthday. Infants and toddlers are children just beginning to discover the world. Can the barbaric and utterly condemnable attack by Hamas on October 7 justify or explain the horrific killing of innocents on this scale?

How can any people who claim to cherish life, steal it away from so many completely innocent children, who had their entire lives ahead of them? This not collateral damage, as some Israeli cynics try to explain it. This is revenge – and the cycle of revenge will continue indefinitely.

Shortly after October 7, I recall an interview with an Israeli soldier who said outright that he ‘needs his revenge.’ Does not that soldier, and everyone who thinks like him, realize that this is precisely how Hamas was operating on October 7? Is it not obvious that revenge, by its very nature, has no end?

It is a mechanical and thoughtless response to injury that repeats itself until one party has the moral strength and courage to say enough is enough: we will not go on slaughtering each other wholesale, exacting retribution on individuals who have committed no wrong, whose deaths are meant only to maximize the suffering of those who loved and cherished them.

Does not every Israeli mother realize that every Palestinian mother cares for their children with the same boundless love that they have for their own? Does Israel truly believe that a Palestinian infant has less value than an Israeli babe-in-arms? Can anyone truthfully believe that the moral response to having one’s innocent loved ones killed is to kill more innocents? And on what scale?

How many dead Palestinian children will it take to satiate the desire for revenge? There is no end, because no matter how many Palestinian children Israel kills, it will not bring back to life a single one of those Israeli younglings that were killed on October 7.

Israel is not honoring its dead by this slaughter and devastation, but just the opposite. It is disgracing the dead and themselves. Israel appears bent on demonstrating before the whole world that it has lost all sense of moral compass, proportionality, pity, and compassion. The Jewish people are better than this: it is they who taught us that to save one human life is to save the world.

The deliberate shedding of innocent blood is and will always be an atrocious act of evil that can never be morally justified. And the time has come for Israel to bring an end to this retribution before it loses its soul and whatever moral sympathy the world had for the wrong it suffered over six months ago.

Prime Minister Netanyahu is justifying this collective punishment by dehumanizing the Palestinians, deeming them unworthy of humane treatment. He is waging a merciless campaign against innocent Palestinians who had nothing to do with Hamas’ acts of terror. For Netanyahu, there is simply no moral equivalence. For him and many of his deplorable followers, the Palestinians are sub-humans, and their lives are unequal to those of Israeli Jews.

Israel will win this war; the question is, will it win it while adhering to Jewish moral values that have guided and ensured their survival throughout the centuries, or win it by leaving behind deep moral wounds that will be etched in memory and history books as one of Israel’s darkest chapters?

They must remember that just about every Arab country will quietly (and some even overtly) cheer the demise of Hamas, but they are and will continue to speak ever louder and clearer about their objection to the killing of innocent Palestinians, especially women and children, and they will scuttle any future prospect of normalization of relations between Israel and other Arab states.

The dehumanization of Palestinians will come back to haunt the Israelis simply because the Palestinians have no other place to go. And whether they are ordinary human beings with hopes and aspirations or subhuman, Israel is stuck with them. And regardless of how the war will end, Israel will have to address the conflict with the Palestinians. The depth of the scars of the war will define the relationship for years to come.

As the death toll and destruction rise in Gaza by the minute, the initial overwhelming sympathy toward Israel’s tragic losses has waned even among many of its friends. Indeed, once Israel loses its moral compass in dealing with the crisis, it will no longer be seen as the victim who rose from the ashes of the Holocaust and has every right to defend itself but the victimizer whose survival rests on the ashes of the Palestinians.

Israel’s ultimate triumph rests on its ability to rise above the fray and adhere to the moral values on which the country was founded and which are the only pillars that can sustain it.

Dr. Alon Ben-Meir is a retired professor of international relations, most recently at the Center for Global Affairs at NYU. He taught courses on international negotiation and Middle Eastern studies.

This article is a selection from Dr Ben-Meir’s upcoming book, A Historic Point of Departure: Bringing the Israeli-Palestinian conflict to a close and creating a new regional geopolitical order, set to be published in April 2024.

IPS UN Bureau

 


!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);